AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $378.29 billion. The enterprise value is $441.47 billion.
Important Dates
The next confirmed earnings date is Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 73.69% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 162.08 and the forward PE ratio is 15.77. AbbVie's PEG ratio is 0.97.
| PE Ratio | 162.08 |
| Forward PE | 15.77 |
| PS Ratio | 6.35 |
| Forward PS | 5.70 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.22 |
| P/OCF Ratio | 18.13 |
| PEG Ratio | 0.97 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.96, with an EV/FCF ratio of 22.43.
| EV / Earnings | 188.02 |
| EV / Sales | 7.40 |
| EV / EBITDA | 14.96 |
| EV / EBIT | 20.76 |
| EV / FCF | 22.43 |
Financial Position
The company has a current ratio of 0.72
| Current Ratio | 0.72 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.31 |
| Debt / FCF | 3.50 |
| Interest Coverage | 7.38 |
Financial Efficiency
Return on equity (ROE) is 137.96% and return on invested capital (ROIC) is 34.14%.
| Return on Equity (ROE) | 137.96% |
| Return on Assets (ROA) | 9.59% |
| Return on Invested Capital (ROIC) | 34.14% |
| Return on Capital Employed (ROCE) | 22.50% |
| Revenue Per Employee | $1.08M |
| Profits Per Employee | $42,691 |
| Employee Count | 55,000 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 3.63 |
Taxes
| Income Tax | -735.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.76% in the last 52 weeks. The beta is 0.35, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +24.76% |
| 50-Day Moving Average | 226.12 |
| 200-Day Moving Average | 206.91 |
| Relative Strength Index (RSI) | 37.20 |
| Average Volume (20 Days) | 6,512,361 |
Short Selling Information
The latest short interest is 19.71 million, so 1.11% of the outstanding shares have been sold short.
| Short Interest | 19.71M |
| Short Previous Month | 18.21M |
| Short % of Shares Out | 1.11% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 3.87 |
Income Statement
In the last 12 months, AbbVie had revenue of $59.64 billion and earned $2.35 billion in profits. Earnings per share was $1.32.
| Revenue | 59.64B |
| Gross Profit | 42.62B |
| Operating Income | 21.27B |
| Pretax Income | 1.66B |
| Net Income | 2.35B |
| EBITDA | 29.52B |
| EBIT | 21.27B |
| Earnings Per Share (EPS) | $1.32 |
Full Income StatementBalance Sheet
The company has $5.67 billion in cash and $68.85 billion in debt, with a net cash position of -$63.18 billion or -$35.75 per share.
| Cash & Cash Equivalents | 5.67B |
| Total Debt | 68.85B |
| Net Cash | -63.18B |
| Net Cash Per Share | -$35.75 |
| Equity (Book Value) | -2.60B |
| Book Value Per Share | -1.49 |
| Working Capital | -10.85B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $20.86 billion and capital expenditures -$1.18 billion, giving a free cash flow of $19.68 billion.
| Operating Cash Flow | 20.86B |
| Capital Expenditures | -1.18B |
| Free Cash Flow | 19.68B |
| FCF Per Share | $11.14 |
Full Cash Flow StatementMargins
Gross margin is 71.46%, with operating and profit margins of 35.65% and 4.00%.
| Gross Margin | 71.46% |
| Operating Margin | 35.65% |
| Pretax Margin | 2.78% |
| Profit Margin | 4.00% |
| EBITDA Margin | 49.49% |
| EBIT Margin | 35.65% |
| FCF Margin | 33.00% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 3.23%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 3.23% |
| Dividend Growth (YoY) | 5.72% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 503.56% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 3.22% |
| Earnings Yield | 0.62% |
| FCF Yield | 5.20% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $239.16, which is 11.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $239.16 |
| Price Target Difference | 11.74% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (5Y) | 6.73% |
| EPS Growth Forecast (5Y) | 41.89% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.21 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 7 |
